title: Cardiovascular therapies and risk for development of diabetes.
abstract: The prevalence of diabetes is increasing, and patients with diabetes are at increased risk of adverse cardiovascular outcomes. Recently, the results from 11 large randomized clinical trials have suggested a difference in the emergence of new diabetes according to cardiovascular medication use. Treatment with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and calcium antagonists yielded a lower incidence of diabetes development than beta-blockers and diuretics. Physicians should consider this possible diabetes consequence when prescribing long-term beta-blockers and diuretics, particularly in patients at high risk of developing diabetes.
authors.affiliation: Division of Cardiovascular Medicine, University of Florida, Gainesville, Florida 32610-0277, USA. pepincj@medicine.ufl.edu
authors.forename: Carl J
authors.initials: CJ
authors.lastname: Pepine
authors.forename: Rhonda M
authors.initials: RM
authors.lastname: Cooper-Dehoff
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage; D002121:Calcium Channel Blockers / Q000008:administration & dosage; D002317:Cardiovascular Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D003920:Diabetes Mellitus / Q000453:epidemiology / Q000517:prevention & control*; D004232:Diuretics / Q000009:adverse effects; D006801:Humans; D015994:Incidence; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D014481:United States / Q000453:epidemiology
chemical_list: D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D002317:Cardiovascular Agents; D004232:Diuretics